tirzepatide in nash the SYNERGY-NASH trial, researchers assessed the efficacy and safety of once-weekly in persons with metabolic dysfunction–associated steatohepatitis (MASH) and moderate or severe fibrosis. Full trial results and Plain Language Summary Tirzepatide for the treatment of

During last Monday's episode of ABC's "The Bachelor," a commercial touted "the revolutionary weight-loss medication everyone is talking about." "With Ro, get the online coaching and care you need to lose 15% of your body weight with one weekly shot," a voiceover for the hot digital-health startup boomed

LAA, long-acting analog

Medications like semaglutide can be expensive, and not all insurance plans cover them for weight loss

A single week without progress, disrupted sleep, hormonal fluctuations around your cycle, or a period of higher stress can all produce a temporary stall that resolves without any medication change

Demographics and baseline characteristics were similar between active treatment groups, whereas the placebo group had a slightly greater baseline body weight, greater proportions of participants in higher BMI groups, and a greater proportion of participants with 5 or more comorbidities (Table 1)